Tudor Investment Corp ET AL Invests $15.38 Million in Henry Schein, Inc. $HSIC

Tudor Investment Corp ET AL purchased a new stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 231,651 shares of the company’s stock, valued at approximately $15,375,000. Tudor Investment Corp ET AL owned 0.20% of Henry Schein as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also modified their holdings of the company. Westwood Holdings Group Inc. acquired a new position in Henry Schein during the 2nd quarter valued at about $20,631,000. AlphaQuest LLC lifted its stake in shares of Henry Schein by 91.8% in the 3rd quarter. AlphaQuest LLC now owns 20,861 shares of the company’s stock worth $1,385,000 after acquiring an additional 9,987 shares during the period. Kettle Hill Capital Management LLC bought a new position in shares of Henry Schein in the third quarter valued at approximately $14,158,000. Berger Financial Group Inc acquired a new position in shares of Henry Schein during the third quarter valued at approximately $2,981,000. Finally, SVB Wealth LLC acquired a new position in shares of Henry Schein during the second quarter valued at approximately $1,415,000. 96.62% of the stock is currently owned by institutional investors.

More Henry Schein News

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Zacks raised its Q4 2027 EPS estimate to $1.62 from $1.44, signaling stronger expected back‑half performance for FY2027. Zacks note
• Positive Sentiment: Zacks boosted its Q3 2027 EPS to $1.49 from $1.42 and lifted FY2027 to $5.76 from $5.68, implying improved full‑year outlook beyond FY2026. Zacks note
• Positive Sentiment: Zacks nudged FY2026 guidance upward to $5.26 from $5.23 and raised Q3 2026 to $1.43 (from $1.39) and Q4 2026 to $1.44 (from $1.43), reflecting incremental improvement to near‑term full‑year estimates. Zacks note
• Neutral Sentiment: Zacks published an FY2028 EPS projection of $6.28 (new/forward‑looking estimate). This provides a growth runway but is not a direct revision to consensus today. Zacks note
• Negative Sentiment: Zacks cut its Q2 2027 EPS forecast to $1.38 from $1.47, a notable downgrade for the mid‑year quarter that may pressure near‑term expectations. Zacks note
• Negative Sentiment: Zacks trimmed Q1 2027 to $1.28 from $1.35 and lowered Q1 2026 to $1.20 from $1.22, indicating weaker near‑term quarterly visibility. Zacks note

Insider Transactions at Henry Schein

In other Henry Schein news, CEO Thomas C. Popeck sold 1,355 shares of the business’s stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $72.79, for a total value of $98,630.45. Following the completion of the sale, the chief executive officer owned 86,182 shares of the company’s stock, valued at $6,273,187.78. The trade was a 1.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Stanley M. Bergman sold 43,812 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $81.31, for a total value of $3,562,353.72. Following the sale, the chief executive officer owned 383,803 shares of the company’s stock, valued at approximately $31,207,021.93. This trade represents a 10.25% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 105,911 shares of company stock valued at $8,574,982 in the last three months. 1.08% of the stock is currently owned by company insiders.

Henry Schein Trading Down 0.6%

Henry Schein stock opened at $72.24 on Friday. The firm has a market cap of $8.29 billion, a price-to-earnings ratio of 22.09, a price-to-earnings-growth ratio of 2.14 and a beta of 0.88. The firm’s 50 day moving average price is $77.72 and its two-hundred day moving average price is $73.01. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.76 and a current ratio of 1.38. Henry Schein, Inc. has a 1 year low of $60.56 and a 1 year high of $89.29.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.30 by $0.04. The company had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.19 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, research analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on HSIC shares. Mizuho upped their target price on Henry Schein from $81.00 to $88.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 25th. UBS Group lifted their price target on Henry Schein from $79.00 to $87.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Robert W. Baird set a $100.00 price objective on Henry Schein and gave the stock an “outperform” rating in a research note on Monday, February 23rd. Barclays began coverage on Henry Schein in a report on Monday, December 8th. They issued an “overweight” rating and a $86.00 price objective for the company. Finally, Wall Street Zen lowered Henry Schein from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 14th. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $85.58.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.